Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study

Acta Chir Belg. 2012 Mar-Apr;112(2):131-8. doi: 10.1080/00015458.2012.11680811.

Abstract

Background: Experience with administration of synbiotics (prebiotics/probiotics) in patients with severe acute pancreatitis (SAP) has demonstrated immunomodulatory capacity. The aim of this trial was evaluation of the feasibility and perspective of early clinical application of oral synbiotic/prebiotic supplements in patients with SAP.

Methods: 90 SAP patients were enrolled during the period from 2005-2008. Patients were stratified according to the feeding mode. CONTROL (n = 32) group received standard whole protein feeding formula. SYNBIO (n = 30) and FIBRE groups (n = 28) received early (within first 24-48 hours) synbiotic or prebiotic supplements. Oral administration of synbiotics or prebiotics was commenced when patients were able to sip water.

Results: Daily provided average volume and calories of synbiotic/prebiotic blends were smaller compared to the CONTROL, p = 0.001. Oral administration of synbiotic/prebiotic supplements was associated with lower infection rate (pancreatic and peripancreatic necrosis) compared to the CONTROL, (p = 0.03; p = 0.001), lower rate of surgical interventions, p = 0.005, shorter ICU (p = 0.05) and hospital stay (p = 0.03). Synbiotic supplemented enteral stimulation of the gut resulted in reduced mortality rate compared to the CONTROL, p = 0.02.

Conclusion: Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut seems to be a potentially valuable complement to the routine treatment protocol of SAP.

Publication types

  • Clinical Trial

MeSH terms

  • Acute Disease
  • Case-Control Studies
  • Dietary Fiber / administration & dosage
  • Dietary Fiber / therapeutic use*
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Pancreatitis / drug therapy*
  • Pancreatitis / mortality
  • Pancreatitis / pathology*
  • Probiotics / administration & dosage
  • Probiotics / therapeutic use*
  • Prospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Survival Analysis
  • Synbiotics* / statistics & numerical data
  • Treatment Outcome

Substances

  • Dietary Fiber